p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis

被引:46
作者
Stuppia, L
Calabrese, G
Peila, R
GuancialiFranchi, P
Morizio, E
Spadano, A
Palka, G
机构
[1] UNIV CHIETI,INST BIOL & GENET,CHIETI,ITALY
[2] CNR,IST CITOMORFOL NORMALE & PATOL,CHIETI,ITALY
[3] OSPED CIVILE PESCARA,DIV EMATOL,PESCARA,ITALY
关键词
D O I
10.1016/S0165-4608(96)00413-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A longitudinal investigation using fluorescence in situ hybridization (FISH) analysis, PCR-SSCP, and in situ detection of apoptosis by the terminal deoxynucleotidyl Transferase (TdT) method was carried out on 23 chronic myelogenous leukemia (CML) patients to study the p53 gene behavior and the apoptotic process during the course of the disease. At diagnosis, FISH showed no loss of the p53 gene on interphase nuclei, and no point mutation was detected by polymerase chain reaction (PCR)single strand conformation polymorphism (SSCP) and sequencing. During the disease course, FISH analysis showed a significative loss of allele (LOA) rate for the p53 gene in eight patients that in seven cases was associated with a suppression of apoptotic process and the progressive expansion of the p53+/p53-clone. DNA sequencing showed in two of these eight patients a point mutation on the other allele, consisting in the formation of a stop codon in one case, and in a frameshift mutation in the other. Six patients had a myeloid blastic crisis (BC), five a lymphoid BC, and the other two an erythroid and an undifferentiated BC, respectively All patients with myeloid BC and the one with undifferentiated BC disclosed a progressive expansion of the clone with p53 loss that was associated with a significant reduction in apoptosis. On the contrary in the 5 patients with lymphoid BC no significant p53 LOA rate was observed during the course of the disease. In these patients apoptotic process also persisted in the acute phase although in a lower rate as compared to CP. (C) Elsevier Science Inc., 1997.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 32 条
[11]  
KELMAN Z, 1989, BLOOD, V74, P2318
[12]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456
[13]  
MASHAL R, 1990, BLOOD, V75, P180
[14]   THE GENE FOR HUMAN P53 CELLULAR TUMOR-ANTIGEN IS LOCATED ON CHROMOSOME-17 SHORT ARM (17P13) [J].
MCBRIDE, OW ;
MERRY, D ;
GIVOL, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (01) :130-134
[15]   MUTATIONS OF THE P53 TUMOR SUPPRESSOR GENE IN HEMATOLOGIC NEOPLASMS [J].
MORI, N ;
WADA, M ;
YOKOTA, J ;
TERADA, M ;
OKADA, M ;
TERAMURA, M ;
MASUDA, M ;
HOSHINO, S ;
MOTOJI, T ;
OSHIMI, K ;
MIZOGUCHI, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (02) :235-240
[16]   HEMIZYGOTIC EXPRESSION OF THE WILD-TYPE P53 ALLELE MAY CONFER A SELECTIVE GROWTH ADVANTAGE BEFORE COMPLETE INACTIVATION OF THE P53 GENE IN THE PROGRESSION OF CHRONIC MYELOGENOUS LEUKEMIA [J].
NAKAI, H ;
MISAWA, S ;
HORIIKE, S ;
MAEKAWA, T ;
KASHIMA, K ;
ISHIZAKI, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) :147-155
[17]   PROGNOSTIC-SIGNIFICANCE OF LOSS OF A CHROMOSOME 17P AND P53 GENE-MUTATIONS IN BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA [J].
NAKAI, H ;
MISAWA, S ;
TANIWAKI, M ;
HORIIKE, S ;
TAKASHIMA, T ;
SERIU, T ;
NAKAGAWA, H ;
FUJII, H ;
SHIMAZAKI, C ;
MARUO, N ;
AKAOGI, T ;
UIKE, N ;
ABE, T ;
KASHIMA, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (02) :425-427
[18]  
NAKAI H, 1992, CANCER RES, V52, P6588
[19]   MUTATIONS IN THE P53 GENE OCCUR IN DIVERSE HUMAN-TUMOR TYPES [J].
NIGRO, JM ;
BAKER, SJ ;
PREISINGER, AC ;
JESSUP, JM ;
HOSTETTER, R ;
CLEARY, K ;
BIGNER, SH ;
DAVIDSON, N ;
BAYLIN, S ;
DEVILEE, P ;
GLOVER, T ;
COLLINS, FS ;
WESTON, A ;
MODALI, R ;
HARRIS, CC ;
VOGELSTEIN, B .
NATURE, 1989, 342 (6250) :705-708
[20]  
OSMAN Y, 1995, EXP HEMATOL, V23, P444